PancreaCell

bioPancreaCell is a startup within the Leonhardt Ventures Cal-X Stars Business Accelerator and Leonhardt’s Launchpads Utah focused on pancreas regeneration.

The company utilizes bioelectric stimulation to control release of specific proteins on demand for specific regenerative purposes in sequence:

1. SDF-1 (stem cell homing factor – recruits a persons own stem cells to stimulated tissues).

2. VEGF (for new blood vessel growth).

3  IGF-1 (for DNA repair at the nucleus level). 

4. Follistatin (for muscle and tissue regeneration).

US08244371-20120814-D000155. RANKL (for demineralization and tissue loosening when needed).

6. Hepatocyte Growth Factor  (tissue regeneration)

7. eNOS (for dilating blood vessels for increasing flow).

8.  Tropoelastin (increases elasticity of any tissues such as skin, arteries, aorta, heart and promotes healing of wounds). 

9. Activin

In extreme cases we combine our regeneration microstimulator with an implantable, programmable, re-fillable stem cell/growth factor micro pump.

In cases of pancreatic cancer we have special signals to stop tumor cell division and blood supply followed by the above regeneration protocol. 

PancreaCell Proposed Clinical Trial Design

Bioelectric Stimulation and Stem Cell Cocktail Micro Infusion for the Treatment of Type 1 Diabetes Mellitus

Sponsor:

PancreaCell a Leonhardt Ventures Co.

Information provided by (Responsible Party):

PancreaCell, Santa Monica, CA

ClinicalTrials.gov Identifier:

 Purpose

Type 1 diabetes mellitus (T1DM) is a chronic, autoimmune condition that involves the progressive destruction of pancreatic β-cells, eventually resulting in the loss of insulin production and secretion. Hence, an effective treatment for T1DM should focus on controlling anti-β-cell autoimmunity, combined with regeneration of lost pancreatic β-cell populations, with minimal risk to the patient.

This is a phase I and II clinical trial for treatment of patient with confirmed diagnosis of T1DM for at least 12 months prior to enrolment in this trial. This study aims to determine the combined effects of bioelectric stimulation controlled protein release and stem cell recruiting, proliferation and differentiation with micro infusion of a stem cell based regenerative cocktail composition and immunomodulation, on regeneration of lost β-cells and halting the immune and inflammation related attack on the pancreatic β-cells, respectively.

Condition

Intervention

Phase

Diabetes Mellitus Type 1

Autoimmune Diseases

Endocrine System Diseases

Glucose Metabolism Disorders

Immune System Diseases

Metabolic Diseases

Biological: Bioelectrical stimulation controlled release of SDF-1 (stem cell homing), IGF-1 (DNA Repair),

HGF, Activin, Follistatin, Tropoelastin, EGF, eNOS and VEGF.   Signals for controlling cell recruitment, 

proliferation and differentiation combined with micro infusion pump programmed delivery of a regenerative

cocktail comprised of mesenchymal stem cells bone marrow derived, BMP-7, IGF-1, HGF, nutrient hydrogel,

pancreatic based matrix, micro RNAs and ant-inflammatory and immunomodulation factors. 

Phase 1

Phase 2

Study Type:

Interventional

Study Design:

Endpoint Classification: Safety/Efficacy Study

Intervention Model: Single Group Assignment

Masking: Open Label

Primary Purpose: Treatment

Official Title:

Efficacy and Safety of Transplantation of Bioelectrical Stimulation Controlled Protein Release and Regenerative Stem Cell Based Cocktail Directly Into Pancreatic Tissue, Combined With Immunomodulation for the Treatment of Type 1 Diabetes Mellitus and a Full Anti-Inflammatory Management Program. 

Resource links provided by NLM:

Genetics Home Reference related topics: type 1 diabetes

MedlinePlus related topics: Autoimmune Diseases Diabetes Type 1 Metabolic Disorders

U.S. FDA Resources 

Further study details as provided by PancreaCell 

Primary Outcome Measures:

  • Exogenous insulin dose [ Time Frame: 1 month ] [ Designated as safety issue: No ]
  • Improvement in Quality of life using a questionnaire [ Time Frame: 1 month ] [ Designated as safety issue: No ]

Secondary Outcome Measures:

  • Anti-GAD titres [ Time Frame: 1 month, 3 months, 6 months, 12 months, 24 months, 36 months ] [ Designated as safety issue: No ]
  • C-peptide level [ Time Frame: 1 month, 3 months, 6 months, 12 months, 24 months, 36 months ] [ Designated as safety issue: No ]
  • HbA1c level [ Time Frame: 1 month, 3 months, 6 months, 12 months, 24 months, 36 months ] [ Designated as safety issue: No ]

Estimated Enrollment:

100

Estimated Study Start Date:

November 2016

Estimated Study Completion Date:

February 2020

Estimated Primary Completion Date:

November 2019 (Final data collection date for primary outcome measure)

Arms

Assigned Interventions

Experimental: Bioelectric Stimulation Protein Release + Stem Cell and Growth Factor Cocktail Direct to Organ Infusion

Bioelectric controlled release of proteins directly in pancreatic tissue and interventional radiology-mediated transplantation of purified, regenerative cocktail into pancreatic tissue and, and intravenous injection of autologous, immunomodulated mononuclear cells and anti-inflammatory agents.

Biological: Bioelectric Stimulation Protein Relase + Stem Cell and Growth Factor Cocktail Direct to Organ Infusion 

Bioelectric controlled release of proteins directly in pancreatic tissue and interventional radiology-mediated transplantation of purified, regenerative cocktail directed into pancreatic tissue and intravenous injection of autologous, immunomodulated mononuclear cells

Detailed Description:

Patients with T1DM depend on administration of exogenous insulin for survival and for control of long-term complications. The best-established treatment is constricted control of blood glucose accomplished by regular daily injections or constant subcutaneous infusion of insulin as intensive insulin therapy. Although insulin therapy has advanced immensely, even the most modern technologies do not allow the maintenance of normal glucose levels.

This is a prospective pilot study intended to treat patients with T1DM after at least one year of confirmed diagnosis. This study encompasses a two-arm approach; the first arm is composed bioelectric stimulation controlled release of proteins (SDF-1, IGF-1, HGF, EGF, Follistatin, Tropoelastin, Activin, eNOS and VEGF), controlled stem cell recruitment by homing signal, controlled proliferation and differentiation and preparation of clinical-grade regenerative cocktail composition (15 components), and direct transplantation weekly of the regenerative cocktail directly into the pancreatic tissue via interventional radiology techniques (a pacing infusion lead with corkscrew tip lodged into pancreas); while the second arm aims at halting the immune attack on pancreatic β-cells through immunomodulation, and is composed of incubation of patient’s leukapheresis with cord blood-derived mesenchymal stem cells for 3-6 hours, and return of the patient’s own white blood cells back into the patient via intravenous injection as well as a full anti-inflammatory infusion and oral intake program led by Omega 3 Fatty Acids. Patients are first mobilised with 10 ug/Kg Granulocyte-Colony Stimulating Factor (GCSF) for five days.

  Eligibility

Ages Eligible for Study:  

8 Years to 55 Years

Genders Eligible for Study:  

Both

Accepts Healthy Volunteers:  

No

Criteria

Inclusion Criteria:

  • Confirmed Type 1 diabetes mellitus diagnosed for at least 12 months prior to execution of this protocol.

Exclusion Criteria:

  • Pregnancy
  • Severe psychiatric disorder
  • Severe organic impairment (renal, hepatic, cardiac, pulmonary)
  • Active infectious disease
  • Previous or present neoplastic disease
  • Any serious complications due to poor control of diabetes, including: lower limb ischemia, kidney failure, liver failure, vision impairment, peripheral neuropathies, poor circulation.

  Contacts and Locations

Italy (TBD), China (4 sites TBD), Mexico,  University of Georgia and University of Miami Diabetes Research Institute

Contact:

Howard J. Leonhardt, Executive Chairman, PancreaCell a Leonhardt Ventures, Co., 1531 6th Street, Unit 401, Santa Monica, CA  90401 email:  hleonhardt@aol.com

  More Information

Responsible Party:

PancreaCell 

ClinicalTrials.gov Identifier:

Other Study ID Numbers:

Study First Received:

****** , 2016

Last Updated:

Health Authority:

FDA

Additional relevant MeSH terms:

Autoimmune Diseases

Diabetes Mellitus

Diabetes Mellitus, Type 1

Endocrine System Diseases

Glucose Metabolism Disorders

Immune System Diseases

Metabolic Diseases

PancreaCell – Leonhardt Ventures

leonhardtventures.com/pancreacell/

PancreaCell is a startup within the Leonhardt Ventures Cal-X Stars Business Accelerator and Leonhardt’s Launchpads Utah focused on pancreas regeneration.

IGF-1

IGF-I mediates regeneration of endocrine pancreas by … – Paperity

paperity.org/…/igf-i-mediates-regeneration-of-endocrine-pancreas-by-incre…

by J Agudo – ‎2008 – ‎Cited by 35 – ‎Related articles

Igf1 expression in beta cells of transgenic mice regenerates the endocrine pancreas during type 1 diabetes. However, the IGF-I-mediated mechanism(s) …

Does IGF-I stimulate pancreatic islet cell growth? – NCBI

www.ncbi.nlm.nih.gov/…

National Center for Biotechnology Information

by JL Liu – ‎2007 – ‎Cited by 23 – ‎Related articles

1. Cell Biochem Biophys. 2007;48(2-3):115-25. … Islet-specificIGF-I overexpression promotes islet cell regeneration in diabetic mice. However, in the last few ..

SDF-1

The SDF-1α/CXCR4 Axis is Required for Proliferation and Maturation …

journals.plos.org/plosone/article?id=10.1371/journal.pone.0038721

by AG Kayali – ‎2012 – ‎Cited by 12 – ‎Related articles

Jun 22, 2012 – Subsequently, a model pancreatic epithelial cell system (CFPAC-1) was … in which the adult mouse pancreasdisplays islet regeneration. Here ..

VEGF

VEGF-A: the inductive angiogenic factor for development … – NCBI

www.ncbi.nlm.nih.gov/…

National Center for Biotechnology Information

by KO Lui – ‎2014 – ‎Cited by 3 – ‎Related articles

Curr Stem Cell Res Ther. 2014;9(5):396-400. VEGF-A: the inductive angiogenic factor for development, regeneration and function of pancreatic beta cells.

HGF

Islet -Cell Mass Preservation and Regeneration in Diabetes Mellitus …

www.hindawi.com/journals/jtrans/2012/230870/

by JM Mellado-Gil – ‎2012 – ‎Cited by 13 – ‎Related articles

Jul 6, 2012 – Pancreatic Islet Development and Regeneration Unit, Department of … Alternative sources of insulinproducing cells are mandatory to fill this gap. …. Indeed, only a marginal mass of islets expressing HGF was required to .

The acquisition of an insulin-secreting phenotype by HGF … – NCBI

www.ncbi.nlm.nih.gov/…

National Center for Biotechnology Information

by E Anastasi – ‎2005 – ‎Cited by 18 – ‎Related articles

We demonstrated that HGF-treated rat pancreatic ductal cellline (ARIP) cells … Humans; Insulin/genetics;Insulin/secretion*; Intracellular Signaling Peptides and … Signaling Peptides and Proteins/metabolism; Islets of Langerhans/cytology …

Hepatocyte growth factor regulates proliferation and differentiation of …

joe.endocrinology-journals.org/…/163.full.pdf

Journal of Endocrinology

by R Wang – ‎2004 – ‎Cited by 27 – ‎Related articles

of epithelial monolayers derived from islets of postnatal ratpancreas … islet-derived epithelial monolayers into insulinproducing cells. We have generated islet-derived epithelial mono- … as HGF in the regulation of mature β-cell function and.

FOLLISTATIN

Overcoming Insulin Insufficiency by Forced Follistatin … – Nature

www.nature.com › Journal home › Archive › Original Articles

Nature

by C Zhao – ‎2015 – ‎Cited by 1 – ‎Related articles

Overexpression of FST in the pancreas of db/db mouse increased β-cell islet mass, … Glucagon-like peptide-1 receptor agonists increase insulin secretion in a ..

eNOS

eNOS deficiency predisposes podocytes to injury in diabetes. – JoVE

www.jove.com/…/enos-deficiency-pre…

Journal of Visualized Experiments

Feb 28, 2013 – Endothelial nitric oxide synthase (eNOS) deficiency may contribute to … Although euglycemia is achieved following pancreatic regeneration, …

The Dual Role of Nitric Oxide in Islet β-Cells – ARTICLES | Physiology

physiologyonline.physiology.org/content/14/2/49

Physiology

by GA Spinas – ‎1999 – ‎Cited by 96 – ‎Related articles

Apr 1, 1999 – Also in insulin-producing cells, NO augments cGMP formation (2). On the …. NO synthase (eNOS) in α-cellsor endothelial cells within the islets …

Activin A

Approaches Towards Endogenous Pancreatic Regeneration – NCBI

www.ncbi.nlm.nih.gov/…

National Center for Biotechnology Information

by M Banerjee – ‎2005 – ‎Cited by 32 – ‎Related articles

Nov 10, 2005 – A combination of activin A and β-cellulin, when tested on neonatal streptozotocin (STZ)-treated rats, resulted in the regeneration of pancreatic …

Remission of Diabetes by [beta]-Cell Regeneration in … – Nature

www.nature.com › Journal home › Archive › Original Articles

Nature

by S Shin – ‎2008 – ‎Cited by 20 – ‎Related articles

It was also reported that combined treatment with activin A and BTC results in the regeneration of pancreatic β cells in neonatal streptozotocin (STZ)-treated rats.

Tropoelastin 

Bioconjugated Hydrogels for Tissue Engineering and Regenerative …

pubs.acs.org/doi/…/acs.bioconjchem.5b0036…

American Chemical Society

by S Ahadian – ‎2015 – ‎Cited by 3 – ‎Related articles

Aug 17, 2015 – However, this approach is not highly efficient for tissue regeneration due to … Some hydrogels (e.g., gelatin methacryloyl (GelMA)(24) and tropoelastin methacryloyl(25)) ….. Myocardial injection of IGF1/HGF-conjugated hydrogels in a rat ….. fibers to enhance the immunoprotection of pancreatic islet cells.

Electrical Stimulation 

Hepatic electrical stimulation reduces blood glucose in diabetic rats

onlinelibrary.wiley.com/doi/10.1111/j.1365…/pdf

John Wiley & Sons

by J Chen – ‎2010 – ‎Cited by 23 – ‎Related articles

May 31, 2010 – glucose using hepatic electrical stimulation(HES). Methods The study was … established that insulinresistance and pancreatic beta-.

Astonishing regeneration potential of the pancreas — ScienceDaily

https://www.sciencedaily.com/releases/…/140820164406.ht

Science Daily

Aug 20, 2014 – Up until puberty, the pancreas is more adaptable and possesses a greater potential for self-healing than had previously been assumed. Type-1 …

[Transcranial electrical stimulation activates the reparative … – NCBI

www.ncbi.nlm.nih.gov/…/1… National Center for Biotechnology Information

by VP Lebedev – ‎2006

Ross Fiziol Zh Im I M Sechenova. 2006 Feb;92(2):204-13. [Transcranial electrical stimulation activates the reparative regeneration and insulinproducing ..

Effect of electrical field stimulation on insulin and glucagon secretion …

www.ncbi.nlm.nih.gov/…

National Center for Biotechnology Information

by E Adeghate – ‎2001 – ‎Cited by 5 – ‎Related articles

The effect of electrical field stimulation (EFS) on insulin (INS) and glucagon (GLU) secretion from normal and diabetic rat pancreas is poorly understood.

PATENTS

Leonhardt Ventures and CerebraCell File Patent Application for …

mysocialgoodnews.com/leonhardt-ventures-cerebracell-file-patent-applic…

Apr 17, 2016 – Leonhardt Ventures and CerebraCell File Patent Application for … Tropinelastin, Hepatocyte Growth Factor, IGF1, eNOS and Activin.

Patent US20050171578 – Method of enhancing myogenesis by …

www.google.com/patents/US20050171578 Google

Aug 4, 2005 – Original Assignee, Leonhardt Howard J. …Patent Drawing … A method of enhancing myogenesis in myocardium comprising the steps of:.

BioLeonhardt Files Provisional Patent Application For … – BioSpace

www.biospace.com/news_story.aspx?StoryID=409221&full=1

Feb 18, 2016 – BioLeonhardt MyoStim is incubating within Cal-X Stars Business … Follistatin-like 1 (FSTL1) is a protein that encourages the growth of healthy ..

IGF-1 Controlled Release by Bioelectric Stimulation Provisional Patent …

mysocialgoodnews.com/igf1-controlled-release-bioelectric-stimulation-…

Apr 2, 2016 – The startups via Leonhardt Ventures have filed a provisional patent …. Patent Application | My Social Good Newson Howard Leonhardt to 

Hyperthermia With Mild Electrical Stimulation Protects … – Diabetes

diabetes.diabetesjournals.org/content/61/4/838.full.pdf Diabetes

by T Kondo – ‎2012 – ‎Cited by 26 – ‎Related articles

treated or treated with heat shock (HS) and mild electrical stimu- …. were used to investigate individualprotein expression by immunohisto- …. lower in the HS+MES-treated mice than in the control mice …. insulin content per nanogram of DNA (I) were measured in islets isolated from HS+MES-treated and sham-treated …

Related Scientific Supporting Articles

IGF-1

IGF-I mediates regeneration of endocrine pancreas by … – Paperity

paperity.org/…/igf-i-mediates-regeneration-of-endocrine-pancreas-by-incre…

by J Agudo – ‎2008 – ‎Cited by 35 – ‎Related articles

Igf1 expression in beta cells of transgenic mice regenerates the endocrine pancreas during type 1 diabetes. However, the IGF-I-mediated mechanism(s) …

Does IGF-I stimulate pancreatic islet cell growth? – NCBI

www.ncbi.nlm.nih.gov/…

National Center for Biotechnology Information

by JL Liu – ‎2007 – ‎Cited by 23 – ‎Related articles

1. Cell Biochem Biophys. 2007;48(2-3):115-25. … Islet-specificIGF-I overexpression promotes islet cell regeneration in diabetic mice. However, in the last few ..

SDF-1

The SDF-1α/CXCR4 Axis is Required for Proliferation and Maturation …

journals.plos.org/plosone/article?id=10.1371/journal.pone.0038721

by AG Kayali – ‎2012 – ‎Cited by 12 – ‎Related articles

Jun 22, 2012 – Subsequently, a model pancreatic epithelial cell system (CFPAC-1) was … in which the adult mouse pancreasdisplays islet regeneration. Here ..

VEGF

VEGF-A: the inductive angiogenic factor for development … – NCBI

www.ncbi.nlm.nih.gov/…

National Center for Biotechnology Information

by KO Lui – ‎2014 – ‎Cited by 3 – ‎Related articles

Curr Stem Cell Res Ther. 2014;9(5):396-400. VEGF-A: the inductive angiogenic factor for development, regeneration and function of pancreatic beta cells.

HGF

Islet -Cell Mass Preservation and Regeneration in Diabetes Mellitus …

www.hindawi.com/journals/jtrans/2012/230870/

by JM Mellado-Gil – ‎2012 – ‎Cited by 13 – ‎Related articles

Jul 6, 2012 – Pancreatic Islet Development and Regeneration Unit, Department of … Alternative sources of insulinproducing cells are mandatory to fill this gap. …. Indeed, only a marginal mass of islets expressing HGF was required to .

The acquisition of an insulin-secreting phenotype by HGF … – NCBI

www.ncbi.nlm.nih.gov/…

National Center for Biotechnology Information

by E Anastasi – ‎2005 – ‎Cited by 18 – ‎Related articles

We demonstrated that HGF-treated rat pancreatic ductal cellline (ARIP) cells … Humans; Insulin/genetics;Insulin/secretion*; Intracellular Signaling Peptides and … Signaling Peptides and Proteins/metabolism; Islets of Langerhans/cytology …

Hepatocyte growth factor regulates proliferation and differentiation of …

joe.endocrinology-journals.org/…/163.full.pdf

Journal of Endocrinology

by R Wang – ‎2004 – ‎Cited by 27 – ‎Related articles

of epithelial monolayers derived from islets of postnatal ratpancreas … islet-derived epithelial monolayers into insulinproducing cells. We have generated islet-derived epithelial mono- … as HGF in the regulation of mature β-cell function and.

FOLLISTATIN

Overcoming Insulin Insufficiency by Forced Follistatin … – Nature

www.nature.com › Journal home › Archive › Original Articles

Nature

by C Zhao – ‎2015 – ‎Cited by 1 – ‎Related articles

Overexpression of FST in the pancreas of db/db mouse increased β-cell islet mass, … Glucagon-like peptide-1 receptor agonists increase insulin secretion in a ..

eNOS

eNOS deficiency predisposes podocytes to injury in diabetes. – JoVE

www.jove.com/…/enos-deficiency-pre…

Journal of Visualized Experiments

Feb 28, 2013 – Endothelial nitric oxide synthase (eNOS) deficiency may contribute to … Although euglycemia is achieved following pancreatic regeneration, …

The Dual Role of Nitric Oxide in Islet β-Cells – ARTICLES | Physiology

physiologyonline.physiology.org/content/14/2/49

Physiology

by GA Spinas – ‎1999 – ‎Cited by 96 – ‎Related articles

Apr 1, 1999 – Also in insulin-producing cells, NO augments cGMP formation (2). On the …. NO synthase (eNOS) in α-cellsor endothelial cells within the islets …

Activin A

Approaches Towards Endogenous Pancreatic Regeneration – NCBI

www.ncbi.nlm.nih.gov/…

National Center for Biotechnology Information

by M Banerjee – ‎2005 – ‎Cited by 32 – ‎Related articles

Nov 10, 2005 – A combination of activin A and β-cellulin, when tested on neonatal streptozotocin (STZ)-treated rats, resulted in the regeneration of pancreatic …

Remission of Diabetes by [beta]-Cell Regeneration in … – Nature

www.nature.com › Journal home › Archive › Original Articles

Nature

by S Shin – ‎2008 – ‎Cited by 20 – ‎Related articles

It was also reported that combined treatment with activin A and BTC results in the regeneration of pancreatic β cells in neonatal streptozotocin (STZ)-treated rats.

Tropoelastin 

Bioconjugated Hydrogels for Tissue Engineering and Regenerative …

pubs.acs.org/doi/…/acs.bioconjchem.5b0036…

American Chemical Society

by S Ahadian – ‎2015 – ‎Cited by 3 – ‎Related articles

Aug 17, 2015 – However, this approach is not highly efficient for tissue regeneration due to … Some hydrogels (e.g., gelatin methacryloyl (GelMA)(24) and tropoelastin methacryloyl(25)) ….. Myocardial injection of IGF1/HGF-conjugated hydrogels in a rat ….. fibers to enhance the immunoprotection of pancreatic islet cells.

Electrical Stimulation 

Hepatic electrical stimulation reduces blood glucose in diabetic rats

onlinelibrary.wiley.com/doi/10.1111/j.1365…/pdf

John Wiley & Sons

by J Chen – ‎2010 – ‎Cited by 23 – ‎Related articles

May 31, 2010 – glucose using hepatic electrical stimulation(HES). Methods The study was … established that insulinresistance and pancreatic beta-.

Astonishing regeneration potential of the pancreas — ScienceDaily

https://www.sciencedaily.com/releases/…/140820164406.ht

Science Daily

Aug 20, 2014 – Up until puberty, the pancreas is more adaptable and possesses a greater potential for self-healing than had previously been assumed. Type-1 …

[Transcranial electrical stimulation activates the reparative … – NCBI

www.ncbi.nlm.nih.gov/…/1… National Center for Biotechnology Information

by VP Lebedev – ‎2006

Ross Fiziol Zh Im I M Sechenova. 2006 Feb;92(2):204-13. [Transcranial electrical stimulation activates the reparative regeneration and insulinproducing ..

Effect of electrical field stimulation on insulin and glucagon secretion …

www.ncbi.nlm.nih.gov/…

National Center for Biotechnology Information

by E Adeghate – ‎2001 – ‎Cited by 5 – ‎Related articles

The effect of electrical field stimulation (EFS) on insulin (INS) and glucagon (GLU) secretion from normal and diabetic rat pancreas is poorly understood.

PATENTS

Leonhardt Ventures and CerebraCell File Patent Application for …

mysocialgoodnews.com/leonhardt-ventures-cerebracell-file-patent-applic…

Apr 17, 2016 – Leonhardt Ventures and CerebraCell File Patent Application for … Tropinelastin, Hepatocyte Growth Factor, IGF1, eNOS and Activin.

Patent US20050171578 – Method of enhancing myogenesis by …

www.google.com/patents/US20050171578 Google

Aug 4, 2005 – Original Assignee, Leonhardt Howard J. …Patent Drawing … A method of enhancing myogenesis in myocardium comprising the steps of:.

BioLeonhardt Files Provisional Patent Application For … – BioSpace

www.biospace.com/news_story.aspx?StoryID=409221&full=1

Feb 18, 2016 – BioLeonhardt MyoStim is incubating within Cal-X Stars Business … Follistatin-like 1 (FSTL1) is a protein that encourages the growth of healthy ..

IGF-1 Controlled Release by Bioelectric Stimulation Provisional Patent …

mysocialgoodnews.com/igf1-controlled-release-bioelectric-stimulation-…

Apr 2, 2016 – The startups via Leonhardt Ventures have filed a provisional patent …. Patent Application | My Social Good Newson Howard Leonhardt to 

Hyperthermia With Mild Electrical Stimulation Protects … – Diabetes

diabetes.diabetesjournals.org/content/61/4/838.full.pdf Diabetes

by T Kondo – ‎2012 – ‎Cited by 26 – ‎Related articles

treated or treated with heat shock (HS) and mild electrical stimu- …. were used to investigate individualprotein expression by immunohisto- …. lower in the HS+MES-treated mice than in the control mice …. insulin content per nanogram of DNA (I) were measured in islets isolated from HS+MES-treated and sham-treated …

Biologists show bioelectrical signals control tumors arising from …

www.news-medical.net/…/Biologists-show-bioelectrical-signals-control-tumors-arising…

May 28, 2014 – “These distant bioelectric signals suppressed tumor growth, despite the cells’ … Prior News New fNIRS -FD instrument can identify affected areas of brain … Tecentriq drug gets FDA approval to treat urothelial carcinoma.